- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07693283
Expression of Target in Endometriotic Lesions
July 8, 2026 updated by: Lei Zhang, Beijing Tsinghua Chang Gung Hospital
To Investigate the Expression of Target in Endometriotic Lesions
Endometriosis is a common gynecological disorder associated with chronic pelvic pain and infertility, which affects women of reproductive age worldwide.
This study aims to investigate the expression patterns of specific molecules in tissue specimens obtained from patients with endometriosis.
The investigators will compare the expression levels of these molecules between endometriotic lesions and normal tissue.
The primary objective of this study is to elucidate the potential roles of these molecules in the pathogenesis of endometriosis.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lei Zhang
- Phone Number: +86 186 0113 0459
- Email: 461458953@qq.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 102218
- Recruiting
- Beijing Tsinghua Changgung Hospital
-
Contact:
- Lei Zhang
- Phone Number: 8618601130459
- Email: 18601130459@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Female reproductive-aged patients with histopathologically confirmed endometriosis .
Patients with malignant gynecological diseases are excluded.
Description
Inclusion Criteria:
- Pathologically confirmed endometriosis via laparoscopy and histopathological examination
- Complete clinical and pathological data available
Exclusion Criteria:
• History of any malignant tumor
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
patients with endometriosis
|
This study involves no prospective interventional measures for participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Expression levels of molecular in endometriotic lesions and adjacent normal tissue
Time Frame: 6 months
|
Standardized pathological histology assessment method
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lei Zhang, Beijing Tsinghua Changgeng Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 13, 2026
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
February 12, 2027
Study Registration Dates
First Submitted
March 26, 2026
First Submitted That Met QC Criteria
July 8, 2026
First Posted (Actual)
July 9, 2026
Study Record Updates
Last Update Posted (Actual)
July 9, 2026
Last Update Submitted That Met QC Criteria
July 8, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 26154-4-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometriosis
-
Fabio BarraCompletedEndometriosis | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis Pelvic | Endometriosis of ColonItaly
-
BioGene Pharmaceutical Ltd.WithdrawnSafety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis ExternaSwitzerland
-
Ospedale Policlinico San MartinoCompletedEndometriosis | Bowel Endometriosis | Endometriosis, Rectum | Endometriosis ColonItaly
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedEndometriosis | Endometriosis-related Pain | Endometriosis Thoracic | Endometriosis of Lung | Endometriosis of PleuraItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis, Rectum | Endometriosis, SigmoidItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownBowel Endometriosis | Endometriosis, RectumItaly
-
Semmelweis UniversityUniversity of PecsNot yet recruitingEndometriosis | Endometriosis Ovary | Endometriosis Rectovaginal Septum
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
-
Ospedale Policlinico San MartinoActive, not recruitingEndometriosis, Rectum | Endometriosis of ColonItaly
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
Clinical Trials on Retrospective molecular expression analysis in endometriosis tissue specimens
-
University Hospital, ToulouseRecruiting
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedColorectal Cancer | Neoplasm of Uncertain Malignant PotentialUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownMelanoma (Skin)France
-
GERCOR - Multidisciplinary Oncology Cooperative...Completed
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
City of Hope Medical CenterOSI PharmaceuticalsCompletedStage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC MelanomaUnited States
-
University of California, DavisNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Completed